Aims: To investigate differences in prostate cancer detection rates according to the level of glomerular filtration rates (GFR).
Materials and Methods: Patients with prostate-specific antigen (PSA) levels of 4.0-10.0 ng/ml were analysed. Age, serum creatinine, estimated GFR, body mass index, total PSA (tPSA), free PSA (fPSA), per cent free PSA (%fPSA), comorbidities, biopsy Gleason sum and per cent positive core were retrospectively reviewed. All parameters were compared to show whether patients with GFR < 60 ml/min/1.73 m2 (group A) have higher risk of prostate cancer than patients with GFR ≥ 60 (group B). The primary endpoint was cancer detection rate and the secondary endpoints were differences in mean tPSA, fPSA, %fPSA and pathologic outcomes.
Results: A total of 1092 men (243 cancer patients) were included. Mean age was 65.8 ± 7.7 years. No differences in mean age and tPSA were found between groups A and B. Mean fPSA, %fPSA and cancer detection rate were significantly higher in group A than group B. The incidence of %fPSA < 25% was significantly lower in group A than in group B. GFR < 60 ml/min/1.73 m2 , fPSA and %fPSA < 25% were significant predictors for the presence of prostate cancer in patients with tPSA between 4 and 10 ng/ml. However, %fPSA < 25% was not a significant predictor for group A.
Conclusions: Because of the increased cancer detection rates in patients with CKD of stage ≥ 3 whose tPSA levels are 4.0-10.0 ng/ml, performing prostate biopsy should be actively considered in patients with CKD.
Written by:
Cho SY, Park S, Lee SB, Son H, Jeong H. Are you the author?
Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea; Harvard School of Dental Medicine, Boston, MA, USA.
Reference: Int J Clin Pract. 2013 Jun;67(6):552-7.
doi: 10.1111/j.1742-1241.2012.03014.x
PubMed Abstract
PMID: 23679906
UroToday.com Prostate Cancer Section
